OBJECTIVE： To systematically review the efficacy and safety of cinacalcet in the treatment of hemodialysis patients with secondary hyperparathyroidism， and provide evidence-based reference for the clinical treatment. METHODS： Retrieved from Medline， Cochrane Library， EMBase and CBM， randomized controlled trials （RCT） about cinacalcet in the treatment of hemodialysis patients with secondary hyperparathyroidism （SHPT） were collected. Meta-analysis was performed by using Rev Man 5.3.5 software after data extract and quality evaluation by Cochrane systematic Rev Man 5.3.5. RESULTS： Totally 7 RCTs were enrolled， involving 1 987 patients. Results of Meta-analysis showed cinacalcet can significantly reduce the rate of surgical parathyroidectomy[RR＝0.23，95％CI（0.06，0.89），P＝0.03]， incidence of fracture[RR＝0.26，95％CI（0.12，0.60），P＝0.002] and increase the incidences of hypocalcemia[RR＝9.81，95％CI（3.92，4.59），P＜0.001]， nausea[RR＝1.97，95％CI（1.58，2.46），P＜0.001] and vomiting[RR＝1.91，95％CI（1.50，2.42），P＜0.001]， while it showed no significant effect on the the incidence of all-cause mortality and cardiovascular death. CONCLUSIONS： The clinical efficacy of cinacalcet in the treatment of hemodialysis patients with secondary hyperparathyroidism is good， but there are common adverse reactions such as nausea and vomiting， hypocalcemia.